



CHEPLAPHARM ASSUMES ITALIAN RIGHTS FOR ALDACTONE®

Greifswald, 02.12.2015: CHEPLAPHARM acquired the product rights for the prescription medication ALDACTONE® in Italy on 09.11.2015, thus boosting its presence within this market that is very important to CHEPLAPHARM.

ALDACTONE® inhibits the effect of the body's own hormone aldosterone, which regulates the salt and water balance. The active ingredient spironolactone is a diuretic that, according to the World Health Organisation, is on the list of essential medicines.

CHEPLAPHARM secured the rights for Austria (formerly Roche) back in 2005. "With this takeover, we are underpinning our international growth strategy and the consistent expansion of our highly ethical niche range," explained the company management.

The estimated annual turnover is in the middle single-figure million range. With this promising investment, CHEPLAPHARM is continuing with its expansion efforts.

About CHEPLAPHARM

CHEPLAPHARM Arzneimittel GmbH was founded in 1998, with its company headquarters situated in Greifswald since the end of 2014. Its subsidiaries are based in Hamburg and Englewood in New Jersey, USA (15 miles from New York).

With a team of experienced experts, CHEPLAPHARM's aim is to offer high-quality medications, dietary supplements, and cosmetics on the market. These products are manufactured under state-of-the-art conditions and strict quality control. CHEPLAPHARM sees itself as a provider of specialty pharma. The focus lies on active ingredient markets and clinical pictures that are too small for pharma corporate groups and generic producers. It is thus possible for CHEPLAPHARM to offer its customers highly individual products. In many pharmaceutical forms and active ingredient markets, CHEPLAPHARM has a unique position.

CHEPLAPHARM holds more than 150 authorisations in more than 100 countries worldwide and has extensive experience in collaborating with our global distribution and marketing partners.

Currently, CHEPLAPHARM employs 90 highly qualified staff members and, together with its subsidiaries, generates an annual turnover of 100 million euros.

Press office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse@cheplapharm.com